This study included 699 patients with severe aortic stenosis and high surgical risk of whom 348 received transcatheter aortic valve replacement (TAVR) and 351 received surgery. Previous reports of the results to one, two and three years and this work published simultaneously in Lancet reports the final follow-up at 5 years.
The mortality at follow-up was 67.8% for the TAVR group and 62.4% in the surgical group (HR 1.04, CI 95% 0.86 to 1.24; p = 0.76). No structural damage to the valve requiring surgery in any of the two groups was observed. Moderate to severe aortic regurgitation occurred in 14% of TAVR group versus 1% of the surgery group, and this was associated with increased mortality at 5 years.
Michael Mack
2015-03-16
Original title: 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial.
